Logo

Myriad Genetics and Abbott Laboratories Unveil Pharmacogenetics Collaboration

Jan 07, 2004

NEW YORK, Jan. 7 (GenomeWeb News) -- Myriad Genetics of Salt Lake City, Utah, and Abbott Laboratories today unveiled a new pharmacogenetics program and announced the expansion of a collaboration between the two companies.

Financial details were not provided. However, Abbott will fund all research under this collaboration and will retain sole ownership of the results. Myriad will have first rights on any personalized medicine products for reference lab uses that may result, the company said in a statement.

The companies will collaborate on research to identify genetic variation within the general population around drug targets in variuous stages of development. Myriad will provide its high-throughput sequencing technologies and  mutation screening software to analyze samples from various populations to identify genetic polymorphisms.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.